Compareing effects of Trimipramine and Placebo on temptation and rate of relapse

The efficacy of Trimipramine in reducing the temptation and rate of relapse of methamphetamine use compared with placebo (clinical trial with a control group)

Status

Recruiting

Phases

Phase 2

Study type

Interventional

Source

IRCT

Registry ID

IRCT20150822023705N12

Enrollment

132

Registered

2019-09-03

Start date

2019-07-06

Completion date

Unknown

Last updated

2019-10-07

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Methamphetamine dependency. Hallucinogen abuse

Interventions

Intervention 1: Intervention group: The group will receive Trimipramine treatment in two months. The daily dose will be two pills that the person will receive 75 mg in the first month and 150 mg in t

Eligibility

Sex/Gender

Male

Inclusion criteria

Inclusion criteria: Gender Male Methamphetamine dependence diagnoses accordingly Diagnostic and Statistical Manual of Mental Disorders fifth edition The dominant use of methamphetamine for at least 6 months Lack of serious psychiatric disorders

Exclusion criteria

Exclusion criteria: Disagreement to participate in the study

Design outcomes

Primary

Measure	Time frame
Temptation. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Temptation Questionnaire.;Relapse. Timepoint: before intervention- 4 weeks later- 8 weeks later. Method of measurement: Relapse Questionnaire.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactHossein Ramyar

Kermanshah University of Medical Sciences

hossein_ramyar@yahoo.com+98 83 3826 4513

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026